Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242339 (dyslipidemia)
 13,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

DE NOVO DIABETES AND CARDIOVASCULAR RISK: Certain kidney transplant recipients who develop de novo diabetes have an unfavorable cardiovascular risk profile, comparable to patients with type 2 diabetes mellitus, with advanced age, dyslipidemia, obesity and high blood pressure. MYOCARDIAL INFARCTION IN THE PERIOPERATIVE PERIOD: Among kidney transplant recipients, those whose risk factors include male gender diabetes, age over 50 years and prior revascularization procedure for coronary artery disease have a higher risk for myocardial infarction in the perioperative period. The usefulness of anticoagulant or beta-blockers as preventive treatment for these high-risk patients remains to be determined. HYPERLIPIDEMIA: A retrospective analysis of 530 kidney transplant recipients demonstrated that a very significant proportion of those with dyslipidemia are not receiving appropriate care although their lipid profile is indicative of a high or very high cardiovascular risk. MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3.5 g/l) occurring after kidney transplantation. CALCINEURIN-INHIBITOR-INDUCED HEMOLYTIC UREMIA SYNDROME: Five to ten percent of patients given calcineurin inhibitors develop a hemolytic uremia syndrome. Sirolimus appears to be a very interesting alternative for immunoprophylaxys against acute rejection.
 ...
PMID:[Complications in kidney transplantation]. 1157 77

Our knowledge about risk factors of atherosclerosis and their associations has considerably changed and improved. The importance of type 2 diabetes and hypertension was detected earlier, hyperlipidemia and dyslipidemia (disturbance of lipoprotein composition) have been recently implemented. We have learnt that the android obesity form and especially visceral fat serve as central trigger-factor of the resulting "metabolic syndrome" and other related disturbances like acute phase proteins, inflammation markers and procoagulatory state. Altogether atherothrombotic events are increased and result in clinically relevant macrovascular disease (myocardial infarction, cerebrovascular und peripheral arterial disease), blood glucose itself causing additionally microvascular disease. The newest comprehensive guidelines of European Associations try to use most of the known factors for treatment guidelines but will fail due to the fact that they cannot be easily used in clinical practice. In additon, visceral fat, that central factor, and body fat mass have not been integrated. We suggest that the risk should be evaluated in the context of body mass index (BMI) and especially of waist circumference which could be THE central intervention factor in the treatment of our patients.
 ...
PMID:[Metabolic syndrome--a high cardiovascular risk?]. 1551 78

IT IS POSSIBLE TO PREDICT THE POPULATION AT RISK FOR ATHEROTHROMBOTIC DISEASE (ATD) WITH HIGH ACCURACY USING ONLY THREE RISK FACTORS: dyslipidemia, cigarette smoking and hypertension. Using a global risk factor graph with the cholesterol retention fraction (CRF, or [low-density lipoprotein cholesterol - high-density lipoprotein cholesterol]/low-density lipoprotein cholesterol) on the vertical axis and systolic blood pressure (SBP) on the horizontal axis, a threshold line can be drawn using CRF-SBP plots (0.74, 100) and (0.49, 140). Eighty-five per cent of all ATD patients in the Bowling Green Study database were observed to lie above this threshold line. Of the 15% of ATD patients with CRF-SBP plots below the threshold line, most were cigarette smokers, leaving only 6% of patients with ATD in the Bowling Green Study database whose risk for ATD could not be predicted by CRF-SBP plot position above the threshold line and/or cigarette smoking status.
 ...
PMID:Prediction of the population at risk for atherothrombotic disease. 1964 14

THE CLINICAL DECISION TO CONTROL RISK FACTORS FOR CARDIOVASCULAR DISEASE (CVD) IN THE ELDERLY TAKES THE FOLLOWINGS INTO CONSIDERATION: (1) the elderly life expectancy; (2) the elderly biological age and functional capacity; (3) the role of cardiovascular disease in the elderly group; (4) the prevalence of risk factors in the elderly; and (5) The effectiveness of treatment of risk factors in the elderly. A large number of studies showed the efficacy of secondary and primary prevention of dyslipidemia in the elderly. However, the only trial that included patients over 80 years was the Heart Protection Study (HPS). Statins are considered the first line therapy for lowering low-density lipoprotein cholesterol (LDL-C). Because lifestyle changes are very difficult to achieve, doctors in general tend to prescribe many drugs to control cardiovascular risk factors. However, healthy food consumption remains a cornerstone in primary and secondary cardiovascular prevention and should be implemented by everyone.
 ...
PMID:Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. 2291 52